PATIENT JOURNEY | Hepatic Artery Infusion Therapy

Intera Oncology

Consultation with Hepatic Artery Infusion (HAI) provider to learn about HAI therapy requirements and eligibility

Scans to rule out cancer spread and confirm eligibility for HAI procedure

Systemic chemotherapy is discontinued 3-4 weeks before surgery



Surgery to implant HAI pump and pump is filled

After-surgery hospital stay

Post-surgery pump flow scan

Discharge from hospital

First HAI pump refill 2 weeks after surgery

Return every 2 weeks for lab testing and pump refills, alternating between floxuridine and heparinized saline

If you cannot keep a required refill appointment, call your HAI provider to ensure your pump doesn't run dry

Systemic chemotherapy is restarted approximately 4 weeks after surgery

Continued follow-up care as determined by your HAI provider to monitor response to treatment

During HAI therapy, inform your HAI provider about travel and activities you plan to do

HAI provider will determine when to discontinue HAI therapy and whether to maintain the pump with periodic refills

Need support along the way?

Contact Intera Oncology's HAI Patient Navigator

SCAN TO CONNECT

The information provided here is for general informational purposes only and should not be considered as medical advice. Every patient's journey is different and may not follow the path exactly as shown. Please consult with an HAI provider to determine your specific treatment plan and talk about the potential risks and benefits of the device.

The Intera 3000 Hepatic Artery Infusion Pump is indicated for the continuous arterial administration of JND Therapeutics Floxuridine for Injection, USP, heparinized saline, and glycerin. The approved labeling for JND Therapeutics Floxuridine for Injection, USP stipulates the indications, contraindications, and warnings for use of the drug in the pump. The Intera 3000 Hepatic Artery Infusion Pump is contraindicated for use in patients with extensive extrahepatic disease or limited hepatic function. Possible adverse events of the pump are those potential risks associated with any implanted drug delivery device and include: catheter thrombosis, bolus path occlusion, vessel thrombosis, pump dislodgement, seroma, or recurrent hematoma, infection, extravasation, catheter shear, dislodgement or leakage, migration, arterial pseudoaneurysm, arterial dissection, and extrahepatic perfusion. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. Please review the full safety information at https://www.interaoncology.com/patients-caregivers/hai-therapy/safety-information.

MKT-175 Rev A